

INFORMATION ONLY

Further Information on Expanded Use of Solvent Detergent Plasma: Education Materials and Ordering Information

Customer Letter # 2023-04

2023-02-07

Dear Colleagues:

Further to customer letter <u>2023-01</u>, below are links to Canadian Blood Services developed education materials to assist our hospital customers with their Octaplasma introduction. These education materials are posted on our Professional Education website.

- <u>Frequently Asked Questions</u> (FAQ). The FAQ document also includes links to the two slide decks listed below.
- Slide deck for clinical teams.
- Slide deck for transfusion medicine laboratory technologists.
- One page summary that can by printed by blood bank staff and provided with Octaplasma units when they are sent to the floor for transfusion.
- Video: Narrated presentation of slide deck for clinical teams (coming soon).
- Video: Narrated presentation of slide deck for medical laboratory technologists (coming soon).

As new resources are posted on our Professional Education website, the links will be shared in a future customer letter.

Please also find attached two important documents from Octapharma.

- Transitioning from FP to Octaplasma Information for Health Care Professionals
- Octaplasma Q&A for Transfusion Medicine Laboratory

More information on the educational materials being developed by Octapharma will be shared in a future Octapharma communication.

Ordering

Starting on the launch date of March 27, 2023, Octaplasma can be ordered from your local Canadian Blood Services distribution site using our Hospital Portal online ordering tool. Octaplasma will be listed in the Hospital Portal in its own Product Type section.

The contingency Blood Component Order Form has been updated, Octaplasma has been added to the Frozen Components section.

Key Dates Reminder

March 27, 2023 – Date when required changes to the ordering process will be completed, hospitals will be able to start ordering Octaplasma for all patient groups.

September 2023 – All hospitals will be expected to order Octaplasma with at least 80% of plasma issues made up by Octaplasma by this date. This date target will be guided by the experience of hospital customers as they transfuse more Octaplasma.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the "Hospital Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Dr. Tanya Petraszko Senior Medical Director, Medical, Laboratory, and Stem Cell Services